Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

Prevalence of Co-Infections of Hepatitis B and C Among Drug Abuse: Prisoners and Its Association With High Risk Behavior

Behrooz Ataei 1 , Payman Adibi 2 , Zary Nokhodian 1 , Marjan Meshkati 3 and Zahra Boroumandfar 4 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Department of Infectious Diseases, Medical School, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Functional Gastroenterology Research Center, Department of Gastroenterology, Medical School, Isfahan University of Medical Sciences, Isfahan, IR Iran
3 Health Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
4 Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: January 01, 2015, 4 (1); e26620
  • Published Online: January 20, 2015
  • Article Type: Research Article
  • Received: August 11, 2014
  • Revised: October 28, 2014
  • Accepted: December 29, 2014
  • DOI: 10.5812/jjcdc.26620

To Cite: Ataei B, Adibi P, Nokhodian Z, Meshkati M, Boroumandfar Z. Prevalence of Co-Infections of Hepatitis B and C Among Drug Abuse: Prisoners and Its Association With High Risk Behavior, Jundishapur J Chronic Dis Care. 2015 ; 4(1):e26620. doi: 10.5812/jjcdc.26620.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Azarkar Z, SharifzadAeh G, Miraki MA. HBV, HCV and HIV prevalence among-south Khorasan prisoners. J Birjand Univ Med Sci. 2007; 14(2): 9-15
  • 2. Rowhani RA, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy. 2004; 15(2): 151-5
  • 3. Communicable disease office. 2010;
  • 4. Urgancı N, Gulec S, Dogan S, Nuhoglu A. Interferon and ribavirin treatment results of patients with HBV–HCV co-infection cured of childhood malignancies. Int J Infect Dis. 2006; 10(6): 453-7
  • 5. Liaw Y. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J gastroenterology. 2002; 37(13): 65-8
  • 6. Roshandel G, Semnani S, Abdolahi N, Besharat S, Kashtkar A, Joshaghani H, et al. The prevalence of Co-infection with HCV and HDV in HBV infected patients in Golestan province of Iran. J Gorgan Univ Med Sci. 2008; 9(4): 61-5
  • 7. Adoga M, Banwat E, Forbi J, Nimzing L, Pam C, Gyar S, et al. Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infection Develop Countries. 2009; 3(7): 539-47
  • 8. La Torre G, Miele L, Chiaradia G, Mannocci A, Reali M, Gasbarrini G, et al. Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. BMC Infect Dis. 2007; 7: 100[DOI][PubMed]
  • 9. Mohtasham A, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of HCV and high-risk behaviors in drug addiction inmates in Rasht, Iran. J Payesh. 2009; 8: 335-41
  • 10. Shamsaddini S, Nasiri Kashani M, Sharifi I, Kajeh K, Pourlashkari M. Prevalence of infectious skin diseases in the central prison of Kerman. Iranian J Dermatol. 2000; 4(13): 19-25
  • 11. Ataei B, Khorvash F, Azadeh S, Nokhodian Z, Kassaian N, Babak A. The prevalence of high risk behaviors among women prisoners in isfahan, iran. J Isfahan Med Sch. 2011; 29(150): 1070-7
  • 12. Miller RW, Forcehimes A, O'Leary M, LaNoue M. Spiritual direction in addiction treatment: Two clinical trials. J Subs Abuse Treat. 2008; 35(4): 434-42
  • 13. Nejat S, Feyzzadeh A, Asghari S, Keshtkar A, Heshmat R. HIV risk factors in Iran; systematic review, meta-analysis and generalized impact fraction approaches. J Payesh. 2007; 6(1): 45-54
  • 14. Diagnostic bioprobes.
  • 15. Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F. [HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counselling on the compliance of proposed tests]. Epidemiologia e prevenzione. 2003; 28(3): 163-8
  • 16. Macalino G, Vlahov D, Sanford C, Patel S, Sabin K, Salas C, et al. Prevalence and Incidence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infections Among Males in Rhode Island Prisons. American J Public Health. 2004; 94(7): 1218-23[DOI]
  • 17. De La Hoya PS, Marco A, García-Guerrero J, Rivera A. Hepatitis C and B prevalence in Spanish prisons. Eur j Clinic Microbiol Infectious Dis. 2011; 30(7): 857-62
  • 18. Sattar SA, Tetro J, Springthorpe VS, Giulivi A. Preventing the spread of hepatitis B and C viruses: where are germicides relevant? Am J Infect Control. 2001; 29(3): 187-97
  • 19. Savabi O, Hasankhani A, Mohamadikhah Z. The Attitude and Practice of Dentists in Relation with HIV and HBV Infected Patients in Isfahan Province. Iran J Med Educ. 2011; 10(5): 868-85
  • 20. Rad M, Kakoei S, Fatahi T. . Evaluation of knowledge, attitude and practice of dental patients of smoking effects on oral health. J Isfahan Dent Sch. 2008; 3(3): 118-25
  • 21. Tortu S, McMahon JM, Hamid R, Neaigus A. Women's drug injection practices in East Harlem: An event analysis in a high-risk community. AIDS Behav. 2003; 7(3): 317-28
  • 22. Imani R, Karymi A, Kasaeeian N. The relevance of related-risk behaviors and seroprevalence of HBV, HCV and HIV infection in intravenous drug users from Shahrekord, Iran, 2004. Shahrekord Univ Med Sci J. 2006; 8(1): 58-62
  • 23. Stark K, Herrmann U, Ehrhardt S, Bienzle U. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiol Infect J. 2006; 134(4): 814-9
  • 24. Ataei B, Salehi A, Javadi AK, Horvash F, Mortazavi A, Kasaeian N, et al. The Frequency of High-risk Behaviors in Intravenous Drug Abusers Referred to Addiction Prohibition Centers in Isfahan, 2010. J Isfahan Med Sch. 2011; 28(114)
  • 25. Cocozella DR, Albuquerque MM, Borzi S, Barrio M, Dascenzo V, Santecchia JC, et al. [Prevalence of hepatic involvement, alcoholism, hepatis B, C and HIV in patients with background history of drug use]. Acta Gastroent Latinoameric J. 2002; 33(4): 177-81
  • 26. Etard JF, Colbachini P, Dromigny JA, Perrier-Gros-Claude JD. Hepatitis C antibodies among blood donors, Senegal, 2001. Emerg Infect Dis. 2003; 9(11): 1492-3
  • 27. Azizi A, Amirian F, Amirian M. Prevalence and Associated Factors of Hepatitis C in Self-introduced Substance Abusers. Hayat. 2011; 17(1): 55-61
  • 28. Mojtahedzadeh V, Razani N, Malekinejad M, Vazirian M, Shoaee S, Zafarghandi MB, et al. Injection drug use in rural Iran: Integrating HIV prevention into Iran’s rural primary health care system. AIDS Behav. 2008; 12(1): 7-12
  • 29. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008; 70(5): 606-11
  • 30. Mohammad K, Asgari F, Fotouhi A, Yousefi A. Prevalence of Hepatitis B Virus (HBV) infection among Iranian prisoners during 2001-2005. J Payesh. 2008; 7(3): 279-86
  • 31. Fadaei Nobari R, Meshkati M, Ataei B, Heidari K, Kassaian N, Nokhodian Z, et al. Positive Hepatitis C Virus Antibody in Cases with History of Intravenous Drug Abuse via Community Announcement: A Useful Experience. J Isfahan Med Sch. 2011; 28: 1546-52
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments